Welcome to our dedicated page for NOVANTA SEC filings (Ticker: NOVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Novanta Inc. filings document the company's operating results, governance matters and capital structure as an operating technology supplier to medical and advanced technology equipment manufacturers. Form 8-K reports furnish earnings releases and financial guidance updates, report board and committee changes, and disclose authorizations for common-share repurchases.
The company's filings also include capital-markets disclosures for Novanta's 6.50% tangible equity units, including underwriting arrangements, unit issuance and related registration-statement references. The definitive proxy statement covers shareholder voting matters, board governance, executive compensation, equity awards and pay-versus-performance information for the company's annual meeting process.
Novanta Inc. reported that Barbara Hulit has resigned from its Board of Directors, as well as from the Audit Committee and the Environmental, Social and Governance Committee. Her resignation was submitted on September 15, 2025 and will be effective November 1, 2025.
The company stated that Ms. Hulit’s decision to resign was not due to any disagreement with Novanta on matters related to its operations, policies or practices. The filing focuses solely on this governance change and does not describe any related operational or financial impacts.
Novanta Inc. reported that its Board of Directors has authorized the repurchase of up to an additional $200.0 million of its outstanding common shares. As of September 18, 2025, $31.0 million remained available under the Company’s 2020 share repurchase authorization, giving a total current repurchase capacity of $231.0 million.
Shares may be bought at the Company’s discretion over time, including via open market purchases, privately negotiated transactions or accelerated share purchase agreements, in accordance with federal securities laws. The program does not require Novanta to repurchase a specific amount, has no set end date, and may be suspended or discontinued, with actual activity depending on factors such as share price, market and economic conditions, cash availability and other investment opportunities.
Matthijs Glastra, who serves as Chief Executive Officer and a director of Novanta Inc. (NOVT), reported a change in beneficial ownership on 09/10/2025. The filing shows 41,487 shares of common stock were transferred from the Anna Maria Vogelaar 2020 Trust to the reporting person’s direct ownership. Following the reported transaction, the reporting person’s direct beneficial ownership is listed as 69,674 shares. The filing also discloses indirect holdings of 54,382 shares in the Matthijs Glastra 2021 Irrevocable Trust and 15,693 shares in the Matthijs Glastra 2023 GRAT. The Form 4 was signed by an attorney-in-fact, John Burke, on 09/11/2025.